ArticleJACC. Asia2024
Catheter Ablation for Ventricular Tachycardia in Patients With Biopsy-Proven Myocarditis.
Article in JACC. Asia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Arrhythmic Burden After Myocarditis: From Molecular Mechanisms to Therapeutic Strategies.European cardiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Catheter ablation (CA) is increasingly recognized as an effective treatment for ventricular tachycardia (VT) in myocarditis patients, although current evidence is based on less robust data. Objectives: The purpose of this study was to confirm CA's efficacy in reducing VT recurrence and to identify arrhythmic risk factors in biopsy-proven myocarditis patients. Methods: In this dual-center, retrospective study, we included 50 patients with biopsy-proven myocarditis and VT. They were divided into 2 groups: CA (n = 23) and non-CA (n = 27), with the primary endpoint being VT recurrence at 1-year follow-up. Results: The average age of participants was 40.8 ± 14.9 years; 48% were men. Over a median 371-day follow-up, 28 (56%) experienced VT recurrence, with 8 patients (35%) in the CA group and 20 patients (74%) in the non-CA group. Kaplan-Meier analysis showed that the rate of VT recurrence in the CA group was significantly lower than in the non-CA group (log-rank Conclusions: CA is significantly associated with reduced VT recurrence in biopsy-proven myocarditis, albeit this association is not observed in cases of acute myocarditis. The acute stage of myocarditis is independently associated with an increased risk of VT recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.